The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has been widespread globally, and …

The emergence of COVID-19 in 2019 has resulted in a significant global health crisis.
Consequently, extensive research was published to understand and mitigate the disease. In …

This review aims to evaluate the efficacy of any vitamin administration (s) in preventing and
managing COVID-19 and/or long-COVID. Databases were searched up to May 2023 to …

COVID-19, caused by SARS-CoV-2, and its variants have spread rapidly across the globe in
the past few years, resulting in millions of deaths worldwide. Hematological diseases and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began churning out
incredulous terror in December 2019. Within several months from its first detection in …

Synopsis Background The UK Medicines and Regulatory Healthcare Agency (MHRA) have
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …

Brazil has high Covid-19 mortality rates, especially among those patients who are intubated.
It is hypothetically considered that these rates may be related to the abusive use of …

Background The advantages and disadvantages of casirivimab-imdevimab for coronavirus
disease 2019 are not well understood. We conducted a systematic review and meta …

ABSTRACT OBJECTIVES To establish a population pharmacokinetics (PopPK) model of
nirmatrelvir in Chinese COVID-19 patients and provide reference for refining the dosing …